|
|
|
prIME Oncology invites you to view exciting news released from the 51st
American Society of Hematology Annual Meeting and Exposition.
|
| |
|
8 DECEMBER 2009
|
 |
|
This expert interview with Hagop Kantarjian, MD, from the M. D. Anderson Cancer Center in Houston, Texas, and Giuseppe Saglio, MD, from the University of Turin, in Turin, Italy, along with a special newsflash and downloadable slides, discusses newly released data concerning the results of the phase III clinical trial evaluating nilotinib efficacy and safety in clinical trials of newly diagnosed Ph+ CML patients (ENESTnd):
Abstract #LBA-1: Nilotinib demonstrates superior efficacy compared with imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase: Results from the international randomized phase III ENESTnd trial
View the eNewsflash from this data release
View the Expert Interview and Opinion with Hagop Kantarjian, MD, and Giuseppe Saglio, MD and access the downloadable slides
|
 |
|
View a special newsflash highlighting newly released data concerning the use of HDAC inhibitors in hematologic malignancies.
Abstract #308: A phase I study of LBH589, a novel histone deacetylase inhibitor in patients with primary myelofibrosis (PMF) and post-polycythemia/essential thrombocythemia myelofibrosis (Post-PV/ET MF)
Abstract #923: Efficacy of panobinostat in phase II study in patients with relapsed/refractory Hodgkin lymphoma (HL) after high-dose chemotherapy with autologous stem cell transplant
Abstract #1855: A phase I study of oral melphalan combined with LBH589 for patients with relapsed or refractory multiple myeloma (MM)
Abstract #3852: A phase IB, multi-center, open-label dose-escalation study of oral panobinostat (LBH589) and I.V. bortezomib in patients with relapsed multiple myeloma
View the eNewsflash from this data release
|
| |
|
7 DECEMBER 2009
|
|
|
|
This expert interview with Hagop Kantarjian, MD, from the M. D.
Anderson Cancer Center in Houston, Texas, and Michele Baccarani, MD,
from the University of Bologna in Bologna, Italy, along with a special
newsflash, discusses the topic of the use of second-generation tyrosine
kinase inhibitors in newly diagnosed CML focusing on the following data
releases:
Abstract #341: Efficacy of nilotinib in patients (Pts) with newly
diagnosed, previously untreated Philadelphia chromosome (Ph)-positive
chronic myelogenous leukemia in early chronic phase (CML-CP)
Abstract #2205: Nilotinib 800 mg daily as frontline therapy of Ph +
chronic myeloid leukemia: Dose delivered and safety profile for the
GIMEMA CML Working Party
Abstract #338: Efficacy of dasatinib in patients (pts) with previously
untreated chronic myelogenous leukemia (CML) in early chronic phase
(CML-CP)
View the eNewsflash from this data release
View the Expert Interview and Opinion with Hagop Kantarjian, MD, and Michele Baccarani, MD
|
|
|
View a special newsflash highlighting newly released data concerning the use of mTOR inhibitors in hematologic malignancies.
Abstract #587: A phase II trial of the oral mTOR inhibitor everolimus
(RAD001) in relapsed or refractory Waldenstrom’s Macroglobulinemia
Abstract #3277: Treatment with mTOR inhibitor, everolimus (RAD001)
overcomes resistance to imatinib in Ph-Leukemia Quiescent or
T315I-mutated cells
Abstract #3850: Phase I/II study with single agent everolimus (RAD001) in patients with relapsed or refractory multiple myeloma
View the eNewsflash from this data release
|
 |
|
|
|
|
|
